Intracellular galectins in cancer cells: Potential new targets for therapy (review)

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1001-1014

  Vladoiu, Maria C ^a   Labrie, Marilyne ^a   St Pierre, Yves ^a  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

Cancer; Galectin; Subcellular localization

Indexed keywords

GALECTIN; PROTEIN BINDING;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; CELL ADHESION; CELL PROLIFERATION; CELL TRANSFORMATION; HUMAN; IMMUNOLOGY; METABOLISM; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TUMOR ESCAPE; TUMOR INVASION;

APOPTOSIS; CELL ADHESION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GALECTINS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; TUMOR ESCAPE;

EID: 84894504470     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2267     Document Type: Review

References (195)

1. Levi G and Teichberg VI: Isolation and physicochemical characterization of electrolectin, a beta-D-galactoside binding lectin from the electric organ of Electrophorus electricus. J Biol Chem 256: 5735-5740, 1981.
2. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, et al: Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev: Aug 1, 2013 (Epub ahead of print).
3. Radosavljevic G, Volarevic V, Jovanovic I, et al: The roles of Galectin-3 in autoimmunity and tumor progression. Immunol Res 52: 100-110, 2012.
4. Van den Brule F, Califice S and Castronovo V: Expression of galectins in cancer: a critical review. Glycoconj J 19: 537-542, 2004.
5. Liu FT and Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer 5: 29-41, 2005.
6. Partridge EA, Le Roy C, Di Guglielmo GM, et al: Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306: 120-124, 2004.
7. Perillo NL, Uittenbogaart CH, Nguyen JT and Baum LG: Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med 185: 1851-1858, 1997.
8. Chiariotti L, Salvatore P, Frunzio R and Bruni CB: Galectin genes: regulation of expression. Glycoconj J 19: 441-449, 2004.
9. Vyakarnam A, Lenneman AJ, Lakkides KM, Patterson RJ and Wang JL: A comparative nuclear localization study of galectin-1 with other splicing components. Exp Cell Res 242: 419-428, 1998.
10. Ose R, Oharaa O and Nagase T: Galectin-1 and galectin-3 mediate protocadherin-24-dependent membrane localization of beta-catenin in colon cancer cell line HCT116. Curr Chem Genomics 6: 18-26, 2012.
11. Gabius HJ, Andre S, Gunsenhauser I, et al: Association of galectin-1- but not galectin-3-dependent parameters with proliferation activity in human neuroblastomas and small cell lung carcinomas. Anticancer Res 22: 405-410, 2002.
12. Biron VA, Iglesias MM, Troncoso MF, et al: Galectin-1: biphasic growth regulation of Leydig tumor cells. Glycobiology 16: 810-821, 2006.
13. Saussez S, Decaestecker C, Lorfevre F, et al: Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology 52: 483-493, 2008.
14. Van den Brule FA, Buicu C, Baldet M, et al: Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun 209: 760-767, 1995.
15. Sanjuan X, Fernandez PL, Castells A, et al: Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 113: 1906-1915, 1997.
16. Dvorankova B, Lacina L, Smetana K Jr, et al: Human galectin-2: nuclear presence in vitro and its modulation by quiescence/stress factors. Histol Histopathol 23: 167-178, 2008.
17. Uhlen M, Oksvold P, Fagerberg L, et al: Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28: 1248-1250, 2010.
18. Viaene AN, Petrof I and Sherman SM: Properties of the thalamic projection from the posterior medial nucleus to primary and secondary somatosensory cortices in the mouse. Proc Natl Acad Sci USA 108: 18156-18161, 2011.
19. Van den Brule FA, Buicu C, Berchuck A, et al: Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27: 1185-1191, 1996.
20. Mey A, Berthier-Vergnes O, Apoil PA, Dore JF and Revillard JP: Expression of the galactose binding protein Mac-2 by human melanoma cell-lines. Cancer Lett 81: 155-163, 1994.
21. Matesa-Anic D, Moslavac S, Matesa N, Cupic H and Kusic Z: Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms. Acta Clin Croat 51: 237-241, 2012.
22. Lotz MM, Andrews CW Jr, Korzelius CA, et al: Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 90: 3466-3470, 1993.
23. Kawachi K, Matsushita Y, Yonezawa S, et al: Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31: 428-433, 2000.
24. Honjo Y, Inohara H, Akahani S, et al: Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 6: 4635-4640, 2000.
25. Kim DW, Kim KH, Yoo BC, et al: Identification of mitochondrial F(1)F(0)-ATP synthase interacting with galectin-3 in colon cancer cells. Cancer Sci 99: 1884-1891, 2008.
26. Lepur A, Carlsson MC, Novak R, Dumic J, Nilsson UJ and Leffler H: Galectin-3 endocytosis by carbohydrate independent and dependent pathways in different macrophage like cell types. Biochim Biophys Acta 1820: 804-818, 2012.
27. Huflejt ME, Jordan ET, Gitt MA, Barondes SH and Leffler H: Strikingly different localization of galectin-3 and galectin-4 in human colon adenocarcinoma T84 cells. Galectin-4 is localized at sites of cell adhesion. J Biol Chem 272: 14294-14303, 1997.
28. Huflejt ME and Leffler H: Galectin-4 in normal tissues and cancer. Glycoconj J 20: 247-255, 2004.
29. Belo AI, van der Sar AM, Tefsen B and van Die I: Galectin-4 reduces migration and metastasis formation of pancreatic cancer cells. PLoS One 8: e65957, 2013.
30. Kuwabara I, Kuwabara Y, Yang RY, et al: Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem 277: 3487-3497, 2002.
31. Kim HJ, Jeon HK, Lee JK, et al: Clinical significance of galectin-7 in epithelial ovarian cancer. Anticancer Res 33: 1555-1561, 2013.
32. De Vasconcelos Carvalho M, Pereira Jdos S, Alves PM, Silveira EJ, de Souza LB and Queiroz LM: Alterations in the immunoexpression of galectins-1, -3 and -7 between different grades of oral epithelial dysplasia. J Oral Pathol Med 42: 174-179, 2013.
33. Villeneuve C, Baricault L, Canelle L, et al: Mitochondrial proteomic approach reveals galectin-7 as a novel BCL-2 binding protein in human cells. Mol Biol Cell 22: 999-1013, 2011.
34. Delgado VM, Nugnes LG, Colombo LL, et al: Modulation of endothelial cell migration and angiogenesis: a novel function for the 'tandem-repeat' lectin galectin-8. FASEB J 25: 242-254, 2011.
35. Kageshita T, Kashio Y, Yamauchi A, et al: Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 99: 809-816, 2002.
36. Irie A, Yamauchi A, Kontani K, et al: Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 11: 2962-2968, 2005.
37. Rousseau C, Muriel MP, Musset M, Botti J and Seve AP: Glycosylated nuclear lectin CBP70 also associated with endoplasmic reticulum and the Golgi apparatus: does the 'classic pathway' of glycosylation also apply to nuclear glycoproteins? J Cell Biochem 78: 638-649, 2000.
38. Hotta K, Funahashi T, Matsukawa Y, et al: Galectin-12, an adipose-expressed galectin-like molecule possessing apoptosis-inducing activity. J Biol Chem 276: 34089-34097, 2001.
39. Wang JL, Gray RM, Haudek KC and Patterson RJ: Nucleocytoplasmic lectins. Biochim Biophys Acta 1673: 75-93, 2004.
40. Carlsson S, Carlsson MC and Leffler H: Intracellular sorting of galectin-8 based on carbohydrate fine specificity. Glycobiology 17: 906-912, 2007.
41. Yang RY, Yu L, Graham JL, et al: Ablation of a galectin preferentially expressed in adipocytes increases lipolysis, reduces adiposity, and improves insulin sensitivity in mice. Proc Natl Acad Sci USA 108: 18696-18701, 2011.
42. Baum LG: Burn control, an adipocyte-specific function for galectin-12. Proc Natl Acad Sci USA 108: 18575-18576, 2011.
43. + regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 110: 1550-1558, 2007.
44. Than NG, Pick E, Bellyei S, et al: Functional analyses of placental protein 13/galectin-13. Eur J Biochem 271: 1065-1078, 2004.
45. Nakai K and Horton P: PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci 24: 34-36, 1999.
46. Nakai K and Kanehisa M: A knowledge base for predicting protein localization sites in eukaryotic cells. Genomics 14: 897-911, 1992.
47. Califice S, Castronovo V, Bracke M and van den Brule F: Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23: 7527-7536, 2004.
48. St-Pierre Y, Campion CG and Grosset AA: A distinctive role for galectin-7 in cancer? Front Biosci (Landmark Ed) 17: 438-450, 2012.
49. Chiariotti L, Berlingieri MT, De Rosa P, et al: Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. Oncogene 7: 2507-2511, 1992.
50. Xu XC, el-Naggar AK and Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 147: 815-822, 1995.
51. Yamaoka K, Mishima K, Nagashima Y, Asai A, Sanai Y and Kirino T: Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J Neurosci Res 59: 722-730, 2000.
52. Paz A, Haklai R, Elad-Sfadia G, Ballan E and Kloog Y: Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 20: 7486-7493, 2001.
53. Elad-Sfadia G, Haklai R, Balan E and Kloog Y: Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 279: 34922-34930, 2004.
54. Shalom-Feuerstein R, Levy R, Makovski V, Raz A and Kloog Y: Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras. Biochim Biophys Acta 1783: 985-993, 2008.
55. Hebert E and Monsigny M: Galectin-3 mRNA level depends on transformation phenotype in ras-transformed NIH 3T3 cells. Biol Cell 81: 73-76, 1994.
56. Hebert E, Roche AC, Nachtigal M and Monsigny M: Transformation but not ras-transfection increases the expression of galectin-3 in human HOS cells. C R Acad Sci III 319: 871-877, 1996.
57. Park JW, Voss PG, Grabski S, Wang JL and Patterson RJ: Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res 29: 3595-3602, 2001.
58. Ellerhorst J, Nguyen T, Cooper DN, Estrov Y, Lotan D and Lotan R: Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1. Int J Oncol 14: 225-232, 1999.
59. Horiguchi N, Arimoto K, Mizutani A, Endo-Ichikawa Y, Nakada H and Taketani S: Galectin-1 induces cell adhesion to the extracellular matrix and apoptosis of non-adherent human colon cancer Colo201 cells. J Biochem 134: 869-874, 2003.
60. Fouillit M, Joubert-Caron R, Poirier F, et al: Regulation of CD45-induced signaling by galectin-1 in Burkitt lymphoma B cells. Glycobiology 10: 413-419, 2000.
61. Poirier F, Bourin P, Bladier D, Joubert-Caron R and Caron M: Effect of 5-azacytidine and galectin-1 on growth and differentiation of the human b lymphoma cell line bl36. Cancer Cell Int 1: 2, 2001.
62. Huang EY, Chen YF, Chen YM, et al: A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. Cell Death Dis 3: e251, 2012.
63. Chung LY, Tang SJ, Sun GH, et al: Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res 18: 4037-4047, 2012.
64. Kim HJ, Jeon HK, Cho YJ, et al: High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer 48: 1914-1921, 2012.
65. Mazurek N, Byrd JC, Sun Y, et al: Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ 19: 523-533, 2012.
66. Shi Y, He B, Kuchenbecker KM, et al: Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells. Int J Cancer 121: 1175-1181, 2007.
67. Matarrese P, Fusco O, Tinari N, et al: Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85: 545-554, 2000.
68. Moon BK, Lee YJ, Battle P, Jessup JM, Raz A and Kim HR: Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol 159: 1055-1060, 2001.
69. Fukumori T, Oka N, Takenaka Y, et al: Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 66: 3114-3119, 2006.
70. Lavra L, Ulivieri A, Rinaldo C, et al: Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J Pathol 218: 66-75, 2009.
71. Lin CI, Whang EE, Abramson MA, et al: Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun 379: 626-631, 2009.
72. Lin CI, Whang EE, Donner DB, et al: Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res 7: 1655-1662, 2009.
73. Hoyer KK, Pang M, Gui D, et al: An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol 164: 893-902, 2004.
74. Cheng YL, Huang WC, Chen CL, et al: Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun 412: 334-340, 2011.
75. Yamamoto-Sugitani M, Kuroda J, Ashihara E, et al: Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci USA 108: 17468-17473, 2011.
76. Oka N, Nakahara S, Takenaka Y, et al: Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res 65: 7546-7553, 2005.
77. Kobayashi T, Shimura T, Yajima T, et al: Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of beta-catenin. Int J Cancer 129: 2775-2786, 2011.
78. Cheong TC, Shin JY and Chun KH: Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci 101: 94-102, 2010.
79. Veschi V, Petroni M, Cardinali B, et al: Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. PLoS One 7: e49139, 2012.
80. Xu Y, Gu X, Gong M, Guo G, Han K and An R: Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment. Cancer Biol Ther 14: 897-906, 2013.
81. Suzuki O and Abe M: Cell surface N-glycosylation and sialylation regulate galectin-3-induced apoptosis in human diffuse large B cell lymphoma. Oncol Rep 19: 743-748, 2008.
82. Demers M, Rose AA, Grosset AA, et al: Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am J Pathol 176: 3023-3031, 2010.
83. Ueda S, Kuwabara I and Liu FT: Suppression of tumor growth by galectin-7 gene transfer. Cancer Res 64: 5672-5676, 2004.
84. Biron-Pain K, Grosset AA, Poirier F, Gaboury L and St-Pierre Y: Expression and functions of galectin-7 in human and murine melanomas. PLoS One 8: e63307, 2013.
85. Matsui Y, Ueda S, Watanabe J, Kuwabara I, Ogawa O and Nishiyama H: Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species. Cancer Res 67: 1212-1220, 2007.
86. Tsai CJ, Sulman EP, Eifel PJ, et al: Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. Gynecol Oncol: Apr 30, 2013 (Epub ahead of print).
87. Zhu H, Wu TC, Chen WQ, et al: Roles of galectin-7 and S100A9 in cervical squamous carcinoma: Clinicopathological and in vitro evidence. Int J Cancer 132: 1051-1059, 2013.
88. Wiersma VR, de Bruyn M, van Ginkel RJ, et al: The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells. J Invest Dermatol 132: 2302-2305, 2012.
89. Yang RY, Hsu DK and Liu FT: Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93: 6737-6742, 1996.
90. Akahani S, Nangia-Makker P, Inohara H, Kim HR and Raz A: Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 57: 5272-5276, 1997.
91. Dumic J, Dabelic S and Flogel M: Galectin-3: an open-ended story. Biochim Biophys Acta 1760: 616-635, 2006.
92. Fukumori T, Takenaka Y, Oka N, et al: Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 64: 3376-3379, 2004.
93. Kopitz J, von Reitzenstein C, Andre S, et al: Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 276: 35917-35923, 2001.
94. Jiang HB, Xu M and Wang XP: Pancreatic stellate cells promote proliferation and invasiveness of human pancreatic cancer cells via galectin-3. World J Gastroenterol 14: 2023-2028, 2008.
95. Song S, Ji B, Ramachandran V, et al: Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One 7: e42699, 2012.
96. Wang LP, Chen SW, Zhuang SM, Li H and Song M: Galectin-3 accelerates the progression of oral tongue squamous cell carcinoma via a Wnt/beta-catenin- dependent pathway. Pathol Oncol Res 19: 461-474, 2013.
97. Zhang D, Chen ZG, Liu SH, et al: Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating beta-catenin. Acta Pharmacol Sin 34: 176-184, 2013.
98. Kim HR, Lin HM, Biliran H and Raz A: Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 59: 4148-4154, 1999.
99. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A and Raz A: Galectin-3, a novel binding partner of beta-catenin. Cancer Res 64: 6363-6367, 2004.
100. Kim SW, Park KC, Jeon SM, et al: Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer. Cell Oncol (Dordr) 36: 169-178, 2013.
101. Satelli A, Rao PS, Thirumala S and Rao US: Galectin-4 functions as a tumor suppressor of human colorectal cancer. Int J Cancer 129: 799-809, 2011.
102. Guo J, Cagatay T, Zhou G, et al: Mutations in the human naked cuticle homolog NKD1 found in colorectal cancer alter Wnt/Dvl/beta-catenin signaling. PLoS One 4: e7982, 2009.
103. Kim SJ, Hwang JA, Ro JY, Lee YS and Chun KH: Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget 4: 1461-1471, 2013.
104. Kopitz J, Andre S, von Reitzenstein C, et al: Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene 22: 6277-6288, 2003.
105. Kobayashi T, Kuroda J, Ashihara E, et al: Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia 24: 843-850, 2010.
106. Nagy N, Bronckart Y, Camby I, et al: Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 50: 392-401, 2002.
107. Yang RY, Hsu DK, Yu L, Ni J and Liu FT: Cell cycle regulation by galectin-12, a new member of the galectin superfamily. J Biol Chem 276: 20252-20260, 2001.
108. Clausse N, van den Brule F, Waltregny D, Garnier F and Castronovo V: Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 3: 317-325, 1999.
109. Hsu YL, Wu CY, Hung JY, Lin YS, Huang MS and Kuo PL: Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin alpha6beta4 and Notch1/Jagged2 signaling pathway. Carcinogenesis 34: 1370-1381, 2013.
110. Hittelet A, Legendre H, Nagy N, et al: Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 103: 370-379, 2003.
111. Spano D, Russo R, Di Maso V, et al: Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med 16: 102-115, 2010.
112. Jung TY, Jung S, Ryu HH, et al: Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg 109: 273-284, 2008.
113. Rorive S, Belot N, Decaestecker C, et al: Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 33: 241-255, 2001.
114. Xue X, Lu Z, Tang D, et al: Galectin-1 secreted by activated stellate cells in pancreatic ductal adenocarcinoma stroma promotes proliferation and invasion of pancreatic cancer cells: an in vitro study on the microenvironment of pancreatic ductal adenocarcinoma. Pancreas 40: 832-839, 2011.
115. Kim HJ, Do IG, Jeon HK, et al: Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer. Hum Pathol 44: 62-68, 2013.
116. Barrow H, Guo X, Wandall HH, et al: Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 17: 7035-7046, 2011.
117. O'Driscoll L, Linehan R, Liang YH, Joyce H, Oglesby I and Clynes M: Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res 22: 3117-3125, 2002.
118. Kim SJ, Choi IJ, Cheong TC, et al: Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 138: 1035-1045.e2, 2010.
119. Kim SJ, Shin JY, Lee KD, et al: Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One 6: e25103, 2011.
120. Wang Y, Nangia-Makker P, Tait L, et al: Regulation of prostate cancer progression by galectin-3. Am J Pathol 174: 1515-1523, 2009.
121. Debray C, Vereecken P, Belot N, et al: Multifaceted role of galectin-3 on human glioblastoma cell motility. Biochem Biophys Res Commun 325: 1393-1398, 2004.
122. Braeuer RR, Zigler M, Kamiya T, et al: Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res 72: 5757-5766, 2012.
123. Radosavljevic G, Jovanovic I, Majstorovic I, et al: Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clin Exp Metastasis 28: 451-462, 2011.
124. Inufusa H, Nakamura M, Adachi T, et al: Role of galectin-3 in adenocarcinoma liver metastasis. Int J Oncol 19: 913-919, 2001.
125. Bresalier RS, Mazurek N, Sternberg LR, et al: Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 115: 287-296, 1998.
126. Ellerhorst JA, Stephens LC, Nguyen T and Xu XC: Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate 50: 64-70, 2002.
127. Demers M, Biron-Pain K, Hebert J, Lamarre A, Magnaldo T and St-Pierre Y: Galectin-7 in lymphoma: elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model. Cancer Res 67: 2824-2829, 2007.
128. Demers M, Magnaldo T and St-Pierre Y: A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression. Cancer Res 65: 5205-5210, 2005.
129. Moisan S, Demers M, Mercier J, Magnaldo T, Potworowski EF and St-Pierre Y: Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype. Leukemia 17: 751-759, 2003.
130. Park JE, Chang WY and Cho M: Induction of matrix metalloproteinase-9 by galectin-7 through p38 MAPK signaling in HeLa human cervical epithelial adenocarcinoma cells. Oncol Rep 22: 1373-1379, 2009.
131. Camby I, Belot N, Rorive S, et al: Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 11: 12-26, 2001.
132. Kasamatsu A, Uzawa K, Nakashima D, et al: Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int J Mol Med 16: 269-273, 2005.
133. Yamauchi A, Kontani K, Kihara M, Nishi N, Yokomise H and Hirashima M: Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. Breast J 12: S196-S200, 2006.
134. Zhang F, Zheng M, Qu Y, et al: Different roles of galectin-9 isoforms in modulating E-selectin expression and adhesion function in LoVo colon carcinoma cells. Mol Biol Rep 36: 823-830, 2009.
135. Zhang F, Zheng MH, Qu Y, et al: Galectin-9 isoforms influence the adhesion between colon carcinoma LoVo cells and human umbilical vein endothelial cells in vitro by regulating the expression of E-selectin in LoVo cells. Zhonghua Zhong Liu Za Zhi 31: 95-98, 2009 (In Chinese).
136. Nobumoto A, Nagahara K, Oomizu S, et al: Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 18: 735-744, 2008.
137. Le Mercier M, Mathieu V, Haibe-Kains B, et al: Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol 67: 456-469, 2008.
138. Ito K, Scott SA, Cutler S, et al: Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis 14: 293-307, 2011.
139. Mourad-Zeidan AA, Melnikova VO, Wang H, Raz A and Bar-Eli M: Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol 173: 1839-1852, 2008.
140. Daroqui CM, Ilarregui JM, Rubinstein N, et al: Regulation of galectin-1 expression by transforming growth factor beta1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape. Cancer Immunol Immunother 56: 491-499, 2007.
141. He J and Baum LG: Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab Invest 86: 578-590, 2006.
142. Tang D, Yuan Z, Xue X, et al: High expression of galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int J Cancer 130: 2337-2348, 2012.
143. Peng W, Wang HY, Miyahara Y, Peng G and Wang RF: Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 68: 7228-7236, 2008.
144. Troncoso MF, Elola MT, Croci DO and Rabinovich GA: Integrating structure and function of 'tandem-repeat' galectins. Front Biosci (Schol Ed) 4: 864-887, 2012.
145. Scott K and Weinberg C: Galectin-1: a bifunctional regulator of cellular proliferation. Glycoconj J 19: 467-477, 2004.
146. Haudek KC, Spronk KJ, Voss PG, Patterson RJ, Wang JL and Arnoys EJ: Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta 1800: 181-189, 2010.
147. Shimura T, Takenaka Y, Fukumori T, et al: Implication of galectin-3 in Wnt signaling. Cancer Res 65: 3535-3537, 2005.
148. Ackerman SJ, Liu L, Kwatia MA, et al: Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion. J Biol Chem 277: 14859-14868, 2002.
149. Swaminathan GJ, Leonidas DD, Savage MP, Ackerman SJ and Acharya KR: Selective recognition of mannose by the human eosinophil Charcot-Leyden crystal protein (galectin-10): a crystallographic study at 1.8 A resolution. Biochemistry 38: 13837-13843, 1999.
150. Satelli A, Rao PS, Gupta PK, Lockman PR, Srivenugopal KS and Rao US: Varied expression and localization of multiple galectins in different cancer cell lines. Oncol Rep 19: 587-594, 2008.
151. Mbeunkui F, Metge BJ, Shevde LA and Pannell LK: Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J Proteome Res 6: 2993-3002, 2007.
152. Khaldoyanidi SK, Glinsky VV, Sikora L, et al: MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem 278: 4127-4134, 2003.
153. Inohara H and Raz A: Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 11: 527-532, 1994.
154. Pienta KJ, Naik H, Akhtar A, et al: Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 87: 348-353, 1995.
155. Nangia-Makker P, Hogan V, Honjo Y, et al: Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94: 1854-1862, 2002.
156. Dings RP, Miller MC, Nesmelova I, et al: Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem 55: 5121-5129, 2012.
157. Chiariotti L, Berlingieri MT, Battaglia C, et al: Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int J Cancer 64: 171-175, 1995.
158. Ellerhorst J, Nguyen T, Cooper DN, Lotan D and Lotan R: Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. Int J Oncol 14: 217-224, 1999.
159. Laderach DJ, Gentilini LD, Giribaldi L, et al: A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res 73: 86-96, 2013.
160. Jung EJ, Moon HG, Cho BI, et al: Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 120: 2331-2338, 2007.
161. Dalotto-Moreno T, Croci DO, Cerliani JP, et al: Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 73: 1107-1117, 2013.
162. Zhao XY, Chen TT, Xia L, et al: Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis 31: 1367-1375, 2010.
163. Camby I, Decaestecker C, Lefranc F, Kaltner H, Gabius HJ and Kiss R: Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun 335: 27-35, 2005.
164. Strik HM, Schmidt K, Lingor P, et al: Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep 18: 483-488, 2007.
165. Le Mercier M, Lefranc F, Mijatovic T, et al: Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 229: 172-183, 2008.
166. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S and Liu FT: Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 91: 167-172, 2001.
167. Wu KL, Huang EY, Jhu EW, et al: Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J Gastroenterol 48: 350-359, 2013.
168. Honjo Y, Nangia-Makker P, Inohara H and Raz A: Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 7: 661-668, 2001.
169. Shekhar MP, Nangia-Makker P, Tait L, Miller F and Raz A: Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol 165: 1931-1941, 2004.
170. Baptiste TA, James A, Saria M and Ochieng J: Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin. Exp Cell Res 313: 652-664, 2007.
171. Van den Brule FA, Waltregny D, Liu FT and Castronovo V: Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89: 361-367, 2000.
172. Yoshii T, Inohara H, Takenaka Y, et al: Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 18: 787-792, 2001.
173. Takenaka Y, Inohara H, Yoshii T, et al: Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett 195: 111-119, 2003.
174. Shankar J, Wiseman SM, Meng F, et al: Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer. J Pathol 228: 56-66, 2012.
175. Li W, Jian-jun W, Xue-Feng Z and Feng Z: CD133(+) human pulmonary adenocarcinoma cells induce apoptosis of CD8(+) T cells by highly expressed galectin-3. Clin Invest Med 33: E44-E53, 2010.
176. Clark MC, Pang M, Hsu DK, et al: Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 120: 4635-4644, 2012.
177. Srinivasan N, Bane SM, Ahire SD, Ingle AD and Kalraiya RD: Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3. Glycoconj J 26: 445-456, 2009.
178. Wang YG, Kim SJ, Baek JH, Lee HW, Jeong SY and Chun KH: Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression. Exp Mol Med 44: 387-393, 2012.
179. Oishi T, Itamochi H, Kigawa J, et al: Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 17: 1040-1046, 2007.
180. Kim MK, Sung CO, Do IG, et al: Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol 16: 352-358, 2011.
181. Merlin J, Stechly L, de Beauce S, et al: Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene 30: 2514-2525, 2011.
182. Kobayashi T, Shimura T, Yajima T, et al: Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells. Clin Exp Metastasis 28: 367-376, 2011.
183. Ideo H, Seko A and Yamashita K: Galectin-4 binds to sulfated glycosphingolipids and carcinoembryonic antigen in patches on the cell surface of human colon adenocarcinoma cells. J Biol Chem 280: 4730-4737, 2005.
184. Kuroda J, Yamamoto M, Nagoshi H, et al: Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res 8: 994-1001, 2010.
185. Gonzalez MM, Yoshizaki L, Wolfenstein-Todel C and Fink NE: Isolation of galectin-1 from human platelets: its interaction with actin. Protein J 31: 8-14, 2012.
186. Pace KE, Lee C, Stewart PL and Baum LG: Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol 163: 3801-3811, 1999.
187. Liu L, Sakai T, Sano N and Fukui K: Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J 380: 31-41, 2004.
188. Seve AP, Felin M, Doyennette-Moyne MA, Sahraoui T, Aubery M and Hubert J: Evidence for a lactose-mediated association between two nuclear carbohydrate-binding proteins. Glycobiology 3: 23-30, 1993.
189. Paron I, Scaloni A, Pines A, et al: Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun 302: 545-553, 2003.
190. Vito P, Pellegrini L, Guiet C and D'Adamio L: Cloning of AIP1, a novel protein that associates with the apoptosis-linked gene ALG-2 in a Ca2+-dependent reaction. J Biol Chem 274: 1533-1540, 1999.
191. Missotten M, Nichols A, Rieger K and Sadoul R: Alix, a novel mouse protein undergoing calcium-dependent interaction with the apoptosis-linked-gene 2 (ALG-2) protein. Cell Death Differ 6: 124-129, 1999.
192. Liu FT, Patterson RJ and Wang JL: Intracellular functions of galectins. Biochim Biophys Acta 1572: 263-273, 2002.
193. Menon RP, Strom M and Hughes RC: Interaction of a novel cysteine and histidine-rich cytoplasmic protein with galectin-3 in a carbohydrate-independent manner. FEBS Lett 470: 227-231, 2000.
194. Bawumia S, Barboni EA, Menon RP and Hughes RC: Specificity of interactions of galectin-3 with Chrp, a cysteine- and histidine-rich cytoplasmic protein. Biochimie 85: 189-194, 2003.
195. Inagaki Y, Higashi K, Kushida M, et al: Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7. Gastroenterology 134: 1180-1190, 2008.